{"id":7411,"date":"2026-04-27T10:15:16","date_gmt":"2026-04-27T02:15:16","guid":{"rendered":"https:\/\/witology.com.tw\/daily-biohealth\/2026-04-27\/"},"modified":"2026-04-27T10:15:16","modified_gmt":"2026-04-27T02:15:16","slug":"9-47","status":"publish","type":"page","link":"https:\/\/witology.com.tw\/en\/daily-biohealth\/9-47\/","title":{"rendered":"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-04-27\uff5cAvalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7"},"content":{"rendered":"\n<style>.wit-daily {\n  --bg:#0f0e0c;--bg2:#16140f;--fg:#e8e3d8;--dim:#8a8276;--mute:#5a5448;\n  --card:#1a1816;--card2:#221f1b;--bdr:#3a342e;--bdr2:#4a423a;\n  --acc:#c4b09a;--acc2:#d4a574;--acc3:#7a6e62;\n  --tw:#e07a6a;--us:#7ab3d4;\n  --up:#8fc78a;--dn:#d97070;--nu:#9a9282;\n  --warn:#d4a574;\n  --line-h:1.85;\n}\n.wit-daily * {margin:0;padding:0;box-sizing:border-box}\n.wit-daily {background:var(--bg)}\n.wit-daily {font-family:\"Noto Sans TC\",sans-serif;background:var(--bg);color:var(--fg);line-height:var(--line-h);-webkit-font-smoothing:antialiased;background-image:radial-gradient(ellipse 80% 40% at 50% 0%,rgba(196,176,154,.06),transparent 70%)}\n.wit-daily .wrap {max-width:860px;margin:0 auto;padding:40px 22px 80px}\n.wit-daily .hdr {text-align:center;padding:64px 0 48px;margin-bottom:48px;border-bottom:1px solid var(--bdr)}\n.wit-daily .hdr-date {font-size:12px;letter-spacing:8px;color:var(--acc);text-transform:uppercase;margin-bottom:14px;font-weight:500}\n.wit-daily .hdr h1 {font-family:\"Noto Serif TC\",serif;font-size:clamp(30px,5vw,46px);font-weight:700;letter-spacing:3px;margin-bottom:12px;background:linear-gradient(135deg,var(--fg) 0%,var(--acc) 100%);-webkit-background-clip:text;-webkit-text-fill-color:transparent;background-clip:text}\n.wit-daily .hdr-sub {font-size:13px;color:var(--dim);letter-spacing:1px}\n.wit-daily .stats {margin-bottom:48px}\n.wit-daily .st {display:flex;align-items:center;gap:12px;margin-bottom:8px}\n.wit-daily .st-bar {height:3px;border-radius:2px;min-width:3px;transition:width .5s;opacity:.85}\n.wit-daily .st-lb {font-size:13px;flex:1;color:var(--fg)}\n.wit-daily .st-ct {font-size:12px;color:var(--dim);min-width:24px;text-align:right;font-variant-numeric:tabular-nums}\n.wit-daily .lbl {font-family:\"Noto Serif TC\",serif;font-size:24px;font-weight:700;color:var(--fg);margin-bottom:28px;padding-bottom:12px;border-bottom:2px solid var(--acc);letter-spacing:1px}\n.wit-daily .c {background:var(--card);border:1px solid var(--bdr);border-radius:4px;margin-bottom:36px;overflow:hidden;box-shadow:0 4px 24px rgba(0,0,0,.35),0 1px 0 rgba(196,176,154,.05) inset;backdrop-filter:blur(16px)}\n.wit-daily .c-hd {display:flex;justify-content:space-between;align-items:center;padding:22px 30px 0}\n.wit-daily .c-cat {font-size:10px;font-weight:700;letter-spacing:3px;text-transform:uppercase;color:var(--cc,var(--acc));border:1px solid var(--cc,var(--acc));padding:3px 12px;border-radius:2px;background:rgba(0,0,0,.2)}\n.wit-daily .c-snt {font-size:13px;font-weight:600;letter-spacing:.5px}\n.wit-daily .s-up {color:var(--up)}\n.wit-daily .s-dn {color:var(--dn)}\n.wit-daily .s-nu {color:var(--nu)}\n.wit-daily .c-t {padding:14px 30px 4px;font-family:\"Noto Serif TC\",serif;font-size:24px;font-weight:700;line-height:1.45;letter-spacing:.5px}\n.wit-daily .c-t a {color:var(--fg);text-decoration:none;transition:color .25s}\n.wit-daily .c-t a:hover {color:var(--acc2)}\n.wit-daily .c-src {padding:0 30px 14px;font-size:12px;color:var(--dim);letter-spacing:.5px}\n.wit-daily .c-hype {display:flex;align-items:center;gap:14px;padding:10px 30px 14px;border-top:1px dashed var(--bdr);border-bottom:1px dashed var(--bdr);background:rgba(196,176,154,.03)}\n.wit-daily .c-hype-lb {font-size:10px;letter-spacing:2px;text-transform:uppercase;color:var(--dim);font-weight:700}\n.wit-daily .c-hype-dots {font-size:14px;color:var(--acc2);letter-spacing:3px;font-family:monospace}\n.wit-daily .c-hype-tx {font-size:12px;color:var(--acc);font-weight:500}\n.wit-daily .c-stocks {padding:14px 30px 18px;display:flex;flex-wrap:wrap;gap:6px}\n.wit-daily .stk {display:inline-flex;align-items:center;gap:4px;font-size:12px;padding:4px 12px;border-radius:2px;font-weight:500}\n.wit-daily .stk b {font-weight:700}\n.wit-daily .stk-tw {background:rgba(224,122,106,.12);color:var(--tw);border:1px solid rgba(224,122,106,.35)}\n.wit-daily .stk-us {background:rgba(122,179,212,.12);color:var(--us);border:1px solid rgba(122,179,212,.35)}\n.wit-daily .stk-other {background:rgba(255,255,255,.04);color:var(--dim);border:1px solid var(--bdr2)}\n.wit-daily .chg {font-size:11px;font-weight:600;padding:1px 6px;border-radius:2px;margin-left:2px}\n.wit-daily .chg-up {background:rgba(226,100,80,.20);color:#ff8f78}\n.wit-daily .chg-down {background:rgba(94,181,141,.20);color:#7ed0a6}\n.wit-daily .chg-flat {background:rgba(255,255,255,.06);color:var(--dim)}\n.wit-daily .c-img {width:100%;height:auto;aspect-ratio:1170\/540;object-fit:cover;border-top:1px solid var(--bdr);border-bottom:1px solid var(--bdr);filter:brightness(.92);display:block}\n.wit-daily .c-analysis {display:grid;grid-template-columns:1fr 1fr;border-top:1px solid var(--bdr)}\n.wit-daily .c-sec {padding:22px 30px;border-bottom:1px solid var(--bdr)}\n.wit-daily .c-sec:nth-child(odd) {border-right:1px solid var(--bdr)}\n.wit-daily .c-wide {grid-column:1\/-1;border-right:none !important}\n.wit-daily .c-sec h4 {font-size:14px;letter-spacing:2px;text-transform:uppercase;color:var(--acc);margin-bottom:12px;font-weight:700}\n.wit-daily .c-sec p {font-size:14px;line-height:var(--line-h);color:var(--fg);opacity:.92}\n.wit-daily .c-counter {background:rgba(212,165,116,.05)}\n.wit-daily .c-counter h4 {color:var(--warn)}\n.wit-daily .c-counter blockquote {border-left:3px solid var(--warn);padding:6px 0 6px 16px;font-size:14px;line-height:var(--line-h);color:var(--fg);opacity:.92;font-style:italic;margin:0}\n.wit-daily .c-watch {background:rgba(196,176,154,.04)}\n.wit-daily .c-watch-grid {display:grid;grid-template-columns:1fr 1fr 1fr;gap:18px;margin-top:6px}\n.wit-daily .c-watch-col {}\n.wit-daily .c-watch-h {font-size:12px;font-weight:700;color:var(--fg);margin-bottom:10px;padding-bottom:6px;border-bottom:1px solid var(--bdr2);display:flex;flex-direction:column;gap:2px}\n.wit-daily .c-watch-h span {font-size:10px;color:var(--dim);letter-spacing:1px;font-weight:400}\n.wit-daily .c-w-short {border-bottom-color:var(--dn)}\n.wit-daily .c-w-mid {border-bottom-color:var(--acc2)}\n.wit-daily .c-w-long {border-bottom-color:var(--up)}\n.wit-daily .c-watch-col ul {list-style:none;padding:0;margin:0}\n.wit-daily .c-watch-col li {font-size:13px;line-height:1.7;color:var(--fg);opacity:.88;padding:6px 0 6px 16px;position:relative}\n.wit-daily .c-watch-col li:before {content:\"\u25b8\";position:absolute;left:0;color:var(--acc);font-size:12px}\n.wit-daily .c-faqs {background:rgba(122,179,212,.04)}\n.wit-daily .c-faqs h4 {color:var(--us)}\n.wit-daily .c-faq-item {border-bottom:1px solid var(--bdr);padding:10px 0}\n.wit-daily .c-faq-item:last-child {border-bottom:none}\n.wit-daily .c-faq-item summary {cursor:pointer;font-size:14px;font-weight:600;color:var(--fg);padding:6px 0;list-style:none;display:flex;align-items:center;gap:10px;transition:color .2s}\n.wit-daily .c-faq-item summary::before {content:\"+\";color:var(--us);font-weight:700;font-size:18px;width:14px;display:inline-block;transition:transform .2s}\n.wit-daily .c-faq-item[open] summary::before {content:\"\u2212\"}\n.wit-daily .c-faq-item summary:hover {color:var(--acc2)}\n.wit-daily .c-faq-item p {font-size:13px;line-height:1.8;color:var(--fg);opacity:.85;padding:8px 0 6px 24px;margin:0}\n.wit-daily .c-ft {padding:16px 30px;border-top:1px solid var(--bdr);text-align:right;background:rgba(0,0,0,.15)}\n.wit-daily .c-ft a {font-size:13px;color:var(--acc);text-decoration:none;font-weight:500;transition:color .25s;letter-spacing:.5px}\n.wit-daily .c-ft a:hover {color:var(--acc2)}\n.wit-daily .briefs {background:var(--card);border:1px solid var(--bdr);border-radius:4px;padding:8px 0;margin-bottom:48px;box-shadow:0 2px 12px rgba(0,0,0,.25)}\n.wit-daily .b-item {display:flex;gap:12px;padding:12px 26px;border-bottom:1px solid var(--bdr);align-items:flex-start}\n.wit-daily .b-item:last-child {border-bottom:none}\n.wit-daily .b-dot {width:7px;height:7px;border-radius:50%;margin-top:9px;flex-shrink:0;box-shadow:0 0 8px currentColor}\n.wit-daily .b-link {color:var(--fg);text-decoration:none;font-size:14px;transition:color .25s;display:block;margin-bottom:2px;line-height:1.6}\n.wit-daily .b-link:hover {color:var(--acc2)}\n.wit-daily .b-meta {font-size:11px;color:var(--dim);letter-spacing:.5px}\n.wit-daily .ftr {text-align:center;padding:36px 0;font-size:11px;color:var(--mute);border-top:1px solid var(--bdr);margin-top:24px;letter-spacing:1px}\n@media(max-width:680px) {.wit-daily .c-analysis {grid-template-columns:1fr}\n.wit-daily .c-sec:nth-child(odd) {border-right:none}\n.wit-daily .c-wide {grid-column:1}\n.wit-daily .c-t {font-size:19px;padding:12px 20px 4px}\n.wit-daily .c-hd, .wit-daily .c-src, .wit-daily .c-stocks, .wit-daily .c-sec, .wit-daily .c-ft, .wit-daily .c-hype {padding-left:20px;padding-right:20px}\n.wit-daily .c-watch-grid {grid-template-columns:1fr;gap:14px}}\n\/* \u5168\u57df(\u975e scoped):\u50c5\u8a72\u7522\u696d\u65e5\u5831\u5b50\u9801\u751f\u6548 *\/\nbody.parent-pageid-7356 .fusion-page-title-bar,\nbody.parent-pageid-7356 .fusion-page-title-row,\nbody.parent-pageid-7356 .fusion-page-title-wrapper {\n  display: none !important;\n  height: 0 !important;\n  padding: 0 !important;\n  margin: 0 !important;\n}\nbody.parent-pageid-7356 #main,\nbody.parent-pageid-7356 #content,\nbody.parent-pageid-7356 .fusion-row,\nbody.parent-pageid-7356 .post-content,\nbody.parent-pageid-7356 article.post {\n  padding-top: 0 !important;\n  margin-top: 0 !important;\n}\n\n\/* scoped(.wit-daily) *\/\n.wit-daily {\n  margin-left: calc((100% - 100vw) \/ 2);\n  margin-right: calc((100% - 100vw) \/ 2);\n  padding-left: calc((100vw - 100%) \/ 2);\n  padding-right: calc((100vw - 100%) \/ 2);\n  padding-top: 40px;\n  padding-bottom: 60px;\n  background: #0f0e0c;\n  color: #e8e3d8;\n  font-family: \"Noto Sans TC\", sans-serif;\n}\n.wit-daily .wrap { padding-left: 22px; padding-right: 22px; padding-top: 0; }\n.wit-daily a { color: inherit; }\n\/* \u5f37\u5236\u8986\u84cb Avada \u4e3b\u984c\u53ef\u80fd\u6ce8\u5165\u7684 blockquote \u767d\u5e95 *\/\n.wit-daily .c-counter blockquote,\n.wit-daily blockquote {\n  background: transparent !important;\n  background-color: transparent !important;\n  color: #e8e3d8 !important;\n  border-left: 3px solid #d4a574 !important;\n  padding: 6px 0 6px 16px !important;\n  font-style: italic !important;\n  margin: 0 !important;\n  box-shadow: none !important;\n}\n.wit-daily .c-counter blockquote::before,\n.wit-daily blockquote::before,\n.wit-daily blockquote::after { content: none !important; }\n<\/style>\n<div class=\"wit-daily\">\n\n<main class=\"wrap\">\n<header class=\"hdr\">\n<div class=\"hdr-date\"><time datetime=\"2026-04-27\">2026 \u5e74 04 \u6708 27 \u65e5<\/time><\/div>\n<h1>\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831<\/h1>\n<p class=\"hdr-sub\">\u5171\u6536\u9304 4 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e \u00b7 3 \u5247\u7cbe\u9078\u6df1\u5ea6\u5206\u6790<\/p>\n<\/header>\n<section aria-labelledby=\"sec-featured\">\n<h2 class=\"lbl\" id=\"sec-featured\">\u7cbe\u9078\u6df1\u5ea6\u5206\u6790<\/h2>\n<article class=\"c\" itemscope=\"\" itemtype=\"https:\/\/schema.org\/NewsArticle\">\n<header class=\"c-hd\">\n<span class=\"c-cat\" style=\"--cc:#4472C4\">\u85e5\u7269<\/span>\n<span class=\"c-snt s-up\">\u25b2 \u504f\u591a<\/span>\n<\/header>\n<h3 class=\"c-t\" itemprop=\"headline\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/avalyn-aims-181m-ipo-fund-phase-3-trials-reformulated-respiratory-drugs\" rel=\"noopener nofollow\" target=\"_blank\">Avalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7\u52a9\u91cd\u65b0\u914d\u65b9\u547c\u5438\u9053\u85e5\u7269\u7b2c\u4e09\u671f\u8a66\u9a57<\/a><\/h3>\n<div class=\"c-src\">\u4f86\u6e90\uff1a<span itemprop=\"publisher\">FierceBiotech<\/span> \u00b7 <time datetime=\"2026-04-27\" itemprop=\"datePublished\">2026-04-27<\/time><\/div>\n<div class=\"c-hype\"><span class=\"c-hype-lb\">\u7522\u696d\u91cd\u8981\u6027<\/span><span class=\"c-hype-dots\">\u25cf\u25cf\u25cb\u25cb\u25cb<\/span><span class=\"c-hype-tx\">2\/5 \u00b7 \u6b21\u8981\u52d5\u614b<\/span><\/div>\n<div class=\"c-stocks\"><span class=\"stk stk-other\">Avalyn Pharma <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-us\"><b>AZN<\/b> AstraZeneca <span class=\"chg chg-down\">\u25bc1.33% $189.75<\/span><\/span><span class=\"stk stk-us\"><b>GSK<\/b> GSK <span class=\"chg chg-down\">\u25bc2.14% $54.44<\/span><\/span><span class=\"stk stk-tw\"><b>4169<\/b> \u6cf0\u5b97\u751f\u7269\u79d1\u6280 <span class=\"chg chg-down\">\u25bc5.39% $158.0<\/span><\/span><span class=\"stk stk-other\"><b>6535<\/b> \u9806\u85e5 <span class=\"chg chg-down\">\u25bc0.80% $124.0<\/span><\/span><\/div>\n<section class=\"c-analysis\" itemprop=\"articleBody\">\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u4e8b\u4ef6<\/h4>\n<p>Avalyn Pharma \u8a08\u5283\u900f\u904e IPO \u52df\u96c6 1.82 \u5104\u7f8e\u5143\u8cc7\u91d1\uff0c\u4e3b\u8981\u7528\u65bc\u63a8\u9032\u5176\u91cd\u65b0\u914d\u65b9\u7684\u547c\u5438\u9053\u85e5\u7269\u9032\u5165\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u3002\u8a72\u516c\u53f8\u5c08\u6ce8\u65bc\u900f\u904e\u5275\u65b0\u7d66\u85e5\u6280\u8853\u6539\u826f\u73fe\u6709\u547c\u5438\u9053\u6cbb\u7642\u85e5\u7269\uff0c\u63d0\u5347\u60a3\u8005\u7528\u85e5\u9806\u5f9e\u6027\u8207\u7642\u6548\u3002<\/p>\n<\/div>\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u6578\u64da<\/h4>\n<p>IPO \u52df\u8cc7\u76ee\u6a19\u70ba 1.82 \u5104\u7f8e\u5143\u3002\u5168\u7403\u547c\u5438\u9053\u75be\u75c5\u6cbb\u7642\u5e02\u5834\u898f\u6a21\u7d04 400 \u5104\u7f8e\u5143\uff0c\u5176\u4e2d COPD \u548c\u6c23\u5598\u6cbb\u7642\u5360\u4e3b\u8981\u4efd\u984d\u3002\u91cd\u65b0\u914d\u65b9\u85e5\u7269\uff08505(b)(2) pathway\uff09\u958b\u767c\u6210\u672c\u7d04\u70ba\u65b0\u85e5\u958b\u767c\u7684 30-50%\uff0c\u958b\u767c\u6642\u9593\u7e2e\u77ed\u81f3 5-7 \u5e74\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide\">\n<h4>\u5e02\u5834\u91cd\u8981\u6027<\/h4>\n<p>\u91cd\u65b0\u914d\u65b9\u7b56\u7565\u4ee3\u8868\u751f\u91ab\u7522\u696d\u6b63\u671d\u5411\u300c\u7cbe\u6e96\u7d66\u85e5\u300d\u548c\u300c\u60a3\u8005\u9ad4\u9a57\u512a\u5316\u300d\u7684\u65b0\u7af6\u722d\u7dad\u5ea6\u767c\u5c55\u3002\u76f8\u8f03\u65bc\u50b3\u7d71\u65b0\u5206\u5b50\u5be6\u9ad4\u85e5\u7269\u52d5\u8f12 10-15 \u5e74\u958b\u767c\u671f\uff0c505(b)(2) \u9014\u5f91\u8b93\u4e2d\u5c0f\u578b\u751f\u6280\u516c\u53f8\u80fd\u4ee5\u66f4\u4f4e\u6210\u672c\u9032\u5165\u6210\u719f\u5e02\u5834\uff0c\u6311\u6230\u5927\u85e5\u5ee0\u65e2\u6709\u7522\u54c1\u7dda\u3002\u9019\u985e\u6a21\u5f0f\u7279\u5225\u9069\u5408\u547c\u5438\u9053\u75be\u75c5\u9818\u57df\uff0c\u56e0\u70ba\u5438\u5165\u5291\u578b\u7684\u5c08\u5229\u4fdd\u8b77\u76f8\u5c0d\u8106\u5f31\uff0c\u7d66\u65b0\u9032\u8005\u66f4\u591a\u6a5f\u6703\u3002\u9577\u671f\u800c\u8a00\uff0c\u6b64\u8da8\u52e2\u5c07\u63a8\u52d5\u85e5\u7269\u50b3\u8f38\u7cfb\u7d71\uff08DDS\uff09\u6280\u8853\u6210\u70ba\u4e0b\u4e00\u500b\u5275\u65b0\u71b1\u9ede\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide c-counter\">\n<h4>\u26a0 \u53cd\u9762\u89c0\u9ede<\/h4>\n<blockquote>\u91cd\u65b0\u914d\u65b9\u7b56\u7565\u96d6\u964d\u4f4e\u958b\u767c\u98a8\u96aa\uff0c\u4f46\u9762\u81e8\u539f\u5ee0\u5c08\u5229\u8a34\u8a1f\u5a01\u8105\u548c FDA \u5c0d\u751f\u7269\u7b49\u6548\u6027\u8981\u6c42\u65e5\u8da8\u56b4\u683c\u7684\u6311\u6230\uff0c\u4e14\u5e02\u5834\u63a5\u53d7\u5ea6\u5f80\u5f80\u4e0d\u5982\u9810\u671f\u6a02\u89c0\u3002<\/blockquote>\n<\/div>\n<div class=\"c-sec c-wide c-watch\">\n<h4>\ud83d\udccd \u63a5\u4e0b\u4f86\u89c0\u5bdf<\/h4>\n<div class=\"c-watch-grid\">\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-short\">\ud83d\udd25 \u77ed\u671f\u50ac\u5316\u5291<span>1-3 \u500b\u6708<\/span><\/div><ul><li>IPO \u5b9a\u50f9\u8207\u8a8d\u8cfc\u60c5\u6cc1<\/li><li>\u7b2c\u4e09\u671f\u8a66\u9a57\u555f\u52d5\u6642\u7a0b\u516c\u544a<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-mid\">\ud83d\udc41 \u4e2d\u671f\u89c0\u5bdf<span>3-12 \u500b\u6708<\/span><\/div><ul><li>\u4e3b\u8981\u7522\u54c1\u7b2c\u4e09\u671f\u8a66\u9a57\u4e2d\u671f\u6578\u64da<\/li><li>\u7af6\u722d\u5c0d\u624b\u5c08\u5229\u8a34\u8a1f\u52d5\u5411<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-long\">\ud83c\udfaf \u9577\u671f\u8b8a\u6578<span>1 \u5e74\u4ee5\u4e0a<\/span><\/div><ul><li>FDA \u5c0d\u91cd\u65b0\u914d\u65b9\u85e5\u7269\u5be9\u67e5\u6a19\u6e96\u8b8a\u5316<\/li><li>\u5927\u85e5\u5ee0\u6536\u8cfc\u6574\u4f75\u8da8\u52e2<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<div class=\"c-sec c-wide c-faqs\">\n<h4>\u2753 \u5e38\u898b\u554f\u984c<\/h4>\n<details class=\"c-faq-item\"><summary>\u91cd\u65b0\u914d\u65b9\u85e5\u7269\u548c\u5b78\u540d\u85e5\u6709\u4ec0\u9ebc\u4e0d\u540c\uff1f<\/summary><p>\u91cd\u65b0\u914d\u65b9\u85e5\u7269\u662f\u6539\u826f\u73fe\u6709\u85e5\u7269\u7684\u5291\u578b\u3001\u7d66\u85e5\u65b9\u5f0f\u6216\u91cb\u653e\u6a5f\u5236\uff0c\u4ecd\u4eab\u6709\u4e00\u5b9a\u5c08\u5229\u4fdd\u8b77\u671f\uff1b\u5b78\u540d\u85e5\u5247\u662f\u5b8c\u5168\u8907\u88fd\u539f\u5ee0\u85e5\uff0c\u7121\u5c08\u5229\u4fdd\u8b77\u4e14\u50f9\u683c\u7af6\u722d\u6fc0\u70c8\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>Avalyn \u7684 1.82 \u5104\u7f8e\u5143\u52df\u8cc7\u898f\u6a21\u5728\u751f\u6280 IPO \u4e2d\u7b97\u5927\u55ce\uff1f<\/summary><p>\u5c6c\u65bc\u4e2d\u7b49\u898f\u6a21\uff0c2024 \u5e74\u751f\u6280 IPO \u5e73\u5747\u52df\u8cc7\u984d\u7d04 1-3 \u5104\u7f8e\u5143\u3002\u8003\u91cf\u547c\u5438\u9053\u85e5\u7269\u7b2c\u4e09\u671f\u8a66\u9a57\u6210\u672c\u76f8\u5c0d\u8f03\u4f4e\uff0c\u6b64\u91d1\u984d\u61c9\u8db3\u4ee5\u652f\u6490\u81f3\u95dc\u9375\u91cc\u7a0b\u7891\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u70ba\u4ec0\u9ebc\u547c\u5438\u9053\u75be\u75c5\u7279\u5225\u9069\u5408\u91cd\u65b0\u914d\u65b9\u7b56\u7565\uff1f<\/summary><p>\u547c\u5438\u9053\u7528\u85e5\u9ad8\u5ea6\u4f9d\u8cf4\u5438\u5165\u88dd\u7f6e\u6280\u8853\uff0c\u60a3\u8005\u5c0d\u4fbf\u5229\u6027\u548c\u526f\u4f5c\u7528\u654f\u611f\u5ea6\u9ad8\uff0c\u4e14\u73fe\u6709\u7522\u54c1\u591a\u5df2\u904e\u5c08\u5229\u4fdd\u8b77\u671f\uff0c\u70ba\u65b0\u914d\u65b9\u7559\u4e0b\u5e02\u5834\u7a7a\u9593\u3002<\/p><\/details>\n<\/div>\n<\/section>\n<footer class=\"c-ft\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/avalyn-aims-181m-ipo-fund-phase-3-trials-reformulated-respiratory-drugs\" rel=\"noopener nofollow\" target=\"_blank\">\u95b1\u8b80\u539f\u6587 \u2192<\/a><\/footer>\n<\/article>\n<article class=\"c\" itemscope=\"\" itemtype=\"https:\/\/schema.org\/NewsArticle\">\n<header class=\"c-hd\">\n<span class=\"c-cat\" style=\"--cc:#70AD47\">\u65b0\u8208\u7642\u6cd5<\/span>\n<span class=\"c-snt s-up\">\u25b2 \u504f\u591a<\/span>\n<\/header>\n<h3 class=\"c-t\" itemprop=\"headline\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo\" rel=\"noopener nofollow\" target=\"_blank\">Eli Lilly 70 \u5104\u7f8e\u5143\u6536\u8cfc Kelonia \u5f8c\uff0c\u9084\u6709\u54ea\u4e9b in vivo CAR-T \u751f\u6280\u516c\u53f8\u53ef\u6536\u8cfc\uff1f<\/a><\/h3>\n<div class=\"c-src\">\u4f86\u6e90\uff1a<span itemprop=\"publisher\">FierceBiotech<\/span> \u00b7 <time datetime=\"2026-04-27\" itemprop=\"datePublished\">2026-04-27<\/time><\/div>\n<div class=\"c-hype\"><span class=\"c-hype-lb\">\u7522\u696d\u91cd\u8981\u6027<\/span><span class=\"c-hype-dots\">\u25cf\u25cf\u25cf\u25cf\u25cb<\/span><span class=\"c-hype-tx\">4\/5 \u00b7 \u91cd\u5927\u8a0a\u865f<\/span><\/div>\n<div class=\"c-stocks\"><span class=\"stk stk-us\"><b>LLY<\/b> Eli Lilly <span class=\"chg chg-down\">\u25bc3.67% $883.96<\/span><\/span><span class=\"stk stk-other\">Kelonia <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-us\"><b>GILD<\/b> Gilead Sciences <span class=\"chg chg-down\">\u25bc2.42% $130.4<\/span><\/span><span class=\"stk stk-us\"><b>BMY<\/b> Bristol Myers Squibb <span class=\"chg chg-down\">\u25bc0.53% $58.71<\/span><\/span><span class=\"stk stk-us\"><b>NVS<\/b> Novartis <span class=\"chg chg-down\">\u25bc1.36% $145.47<\/span><\/span><span class=\"stk stk-tw\"><b>3176<\/b> \u57fa\u4e9e <span class=\"chg chg-flat\">\u2014<\/span><\/span><span class=\"stk stk-tw\"><b>1784<\/b> \u8a0a\u806f <span class=\"chg chg-flat\">\u2014<\/span><\/span><\/div>\n<section class=\"c-analysis\" itemprop=\"articleBody\">\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u4e8b\u4ef6<\/h4>\n<p>Eli Lilly \u4ee5 70 \u5104\u7f8e\u5143\u6536\u8cfc in vivo CAR-T \u6280\u8853\u516c\u53f8 Kelonia\uff0c\u5f15\u767c\u5e02\u5834\u95dc\u6ce8\u5269\u9918\u6a19\u7684\u7a00\u7f3a\u6027\u3002In vivo CAR-T \u6280\u8853\u53ef\u76f4\u63a5\u5728\u60a3\u8005\u9ad4\u5167\u6539\u9020 T \u7d30\u80de\uff0c\u907f\u514d\u50b3\u7d71 ex vivo CAR-T \u7684\u9ad8\u6210\u672c\u8207\u88fd\u9020\u8907\u96dc\u6027\u554f\u984c\u3002<\/p>\n<\/div>\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u6578\u64da<\/h4>\n<p>Kelonia \u6536\u8cfc\u91d1\u984d\u70ba 70 \u5104\u7f8e\u5143\u3002\u5168\u7403 CAR-T \u5e02\u5834\u9810\u4f30 2030 \u5e74\u5c07\u9054 350 \u5104\u7f8e\u5143\uff0c\u5176\u4e2d in vivo \u6280\u8853\u9810\u671f\u5360\u6bd4\u5c07\u5f9e\u76ee\u524d\u4e0d\u8db3 5% \u63d0\u5347\u81f3 25%\u3002\u50b3\u7d71 CAR-T \u7642\u6cd5\u6bcf\u7642\u7a0b\u6210\u672c\u7d04 30-40 \u842c\u7f8e\u5143\uff0cin vivo \u6280\u8853\u6709\u671b\u964d\u81f3 5-10 \u842c\u7f8e\u5143\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide\">\n<h4>\u5e02\u5834\u91cd\u8981\u6027<\/h4>\n<p>In vivo CAR-T \u6280\u8853\u6b63\u6210\u70ba\u4e0b\u4e00\u4ee3\u7d30\u80de\u6cbb\u7642\u7684\u95dc\u9375\u7af6\u722d\u9ad8\u5730\uff0c\u5c07\u5fb9\u5e95\u6539\u5beb\u7d30\u80de\u6cbb\u7642\u7684\u6210\u672c\u7d50\u69cb\u8207\u53ef\u53ca\u6027\u3002\u76f8\u8f03\u65bc\u9700\u8981\u5c08\u696d\u7d30\u80de\u88fd\u9020\u8a2d\u65bd\u7684\u50b3\u7d71 CAR-T\uff0cin vivo \u6280\u8853\u53ef\u671b\u5c07\u7d30\u80de\u6cbb\u7642\u666e\u53ca\u5230\u66f4\u591a\u91ab\u9662\uff0c\u5927\u5e45\u64f4\u5c55\u5e02\u5834\u898f\u6a21\u3002Lilly \u6b64\u8209\u986f\u793a\u5927\u85e5\u5ee0\u5df2\u5c07 in vivo \u5e73\u53f0\u8996\u70ba\u6230\u7565\u5fc5\u722d\u4e4b\u5730\uff0c\u9810\u671f\u5c07\u5f15\u767c\u66f4\u591a\u6536\u8cfc\u7af6\u8cfd\u3002\u9019\u5c0d\u638c\u63e1\u57fa\u56e0\u8f09\u9ad4\u3001\u8102\u8cea\u5948\u7c73\u7c92\u5b50\u7b49\u95dc\u9375\u6280\u8853\u7684\u516c\u53f8\u5f62\u6210\u91cd\u5927\u5229\u591a\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide c-counter\">\n<h4>\u26a0 \u53cd\u9762\u89c0\u9ede<\/h4>\n<blockquote>In vivo CAR-T \u6280\u8853\u4ecd\u9762\u81e8\u57fa\u56e0\u8f09\u9ad4\u5b89\u5168\u6027\u7591\u616e\u548c\u9ad4\u5167\u7de8\u8f2f\u6548\u7387\u4e0d\u7a69\u5b9a\u7b49\u6280\u8853\u74f6\u9838\uff0c70 \u5104\u7f8e\u5143\u4f30\u503c\u53ef\u80fd\u904e\u65bc\u6a02\u89c0\uff0c\u5be6\u969b\u81e8\u5e8a\u8868\u73fe\u6050\u96e3\u7b26\u5408\u671f\u5f85\u3002<\/blockquote>\n<\/div>\n<div class=\"c-sec c-wide c-watch\">\n<h4>\ud83d\udccd \u63a5\u4e0b\u4f86\u89c0\u5bdf<\/h4>\n<div class=\"c-watch-grid\">\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-short\">\ud83d\udd25 \u77ed\u671f\u50ac\u5316\u5291<span>1-3 \u500b\u6708<\/span><\/div><ul><li>\u5176\u4ed6\u5927\u85e5\u5ee0\u6536\u8cfc\u52d5\u4f5c<\/li><li>Kelonia \u6280\u8853\u5e73\u53f0\u8a73\u7d30\u6578\u64da\u516c\u5e03<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-mid\">\ud83d\udc41 \u4e2d\u671f\u89c0\u5bdf<span>3-12 \u500b\u6708<\/span><\/div><ul><li>\u9996\u6279 in vivo CAR-T \u81e8\u5e8a\u8a66\u9a57\u7d50\u679c<\/li><li>\u7af6\u722d\u5c0d\u624b\u6280\u8853\u5e73\u53f0\u6bd4\u8f03<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-long\">\ud83c\udfaf \u9577\u671f\u8b8a\u6578<span>1 \u5e74\u4ee5\u4e0a<\/span><\/div><ul><li>FDA \u5c0d in vivo \u57fa\u56e0\u7de8\u8f2f\u76e3\u7ba1\u6846\u67b6<\/li><li>\u88fd\u9020\u6210\u672c\u5be6\u969b\u4e0b\u964d\u5e45\u5ea6\u9a57\u8b49<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<div class=\"c-sec c-wide c-faqs\">\n<h4>\u2753 \u5e38\u898b\u554f\u984c<\/h4>\n<details class=\"c-faq-item\"><summary>In vivo CAR-T \u548c\u50b3\u7d71 CAR-T \u6709\u4ec0\u9ebc\u5dee\u5225\uff1f<\/summary><p>\u50b3\u7d71 CAR-T \u9700\u5c07\u60a3\u8005 T \u7d30\u80de\u53d6\u51fa\u9ad4\u5916\u6539\u9020\u518d\u8f38\u56de\uff0cin vivo CAR-T \u5247\u76f4\u63a5\u5728\u60a3\u8005\u9ad4\u5167\u900f\u904e\u57fa\u56e0\u8f09\u9ad4\u6539\u9020 T \u7d30\u80de\uff0c\u7701\u53bb\u8907\u96dc\u7684\u7d30\u80de\u88fd\u9020\u6d41\u7a0b\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>70 \u5104\u7f8e\u5143\u6536\u8cfc\u50f9\u5728\u751f\u6280\u4f75\u8cfc\u4e2d\u7b97\u9ad8\u55ce\uff1f<\/summary><p>\u5c6c\u65bc\u8fd1\u5e74\u4f86\u7d30\u80de\u6cbb\u7642\u9818\u57df\u7684\u9802\u7d1a\u4ea4\u6613\uff0c\u53cd\u6620 Lilly \u5c0d in vivo \u5e73\u53f0\u6280\u8853\u7684\u9ad8\u5ea6\u91cd\u8996\uff0c\u4ee5\u53ca\u5e02\u5834\u5c0d\u6b64\u6280\u8853\u5546\u696d\u5316\u6f5b\u529b\u7684\u6a02\u89c0\u9810\u671f\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u9084\u6709\u54ea\u4e9b\u516c\u53f8\u64c1\u6709\u985e\u4f3c\u7684 in vivo CAR-T \u6280\u8853\uff1f<\/summary><p>\u4e3b\u8981\u6a19\u7684\u5305\u62ec Poseida Therapeutics\u3001Ensoma\u3001\u4ee5\u53ca\u90e8\u5206\u5c08\u7cbe\u57fa\u56e0\u8f09\u9ad4\u6280\u8853\u7684\u79c1\u4eba\u516c\u53f8\uff0c\u4f46\u6578\u91cf\u7a00\u5c11\u4e14\u591a\u5df2\u88ab\u5927\u85e5\u5ee0\u95dc\u6ce8\u3002<\/p><\/details>\n<\/div>\n<\/section>\n<footer class=\"c-ft\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo\" rel=\"noopener nofollow\" target=\"_blank\">\u95b1\u8b80\u539f\u6587 \u2192<\/a><\/footer>\n<\/article>\n<article class=\"c\" itemscope=\"\" itemtype=\"https:\/\/schema.org\/NewsArticle\">\n<header class=\"c-hd\">\n<span class=\"c-cat\" style=\"--cc:#5B9BD5\">\u6578\u4f4d\u5065\u5eb7\u91ab\u7642\u79d1\u6280<\/span>\n<span class=\"c-snt s-nu\">\u25ac \u4e2d\u6027<\/span>\n<\/header>\n<h3 class=\"c-t\" itemprop=\"headline\"><a href=\"https:\/\/www.fiercebiotech.com\/cro\/wcg-acquires-contract-network-aiming-streamline-clinical-trial-process\" rel=\"noopener nofollow\" target=\"_blank\">WCG \u6536\u8cfc The Contract Network \u4ee5\u512a\u5316\u81e8\u5e8a\u8a66\u9a57\u57f7\u884c\u6d41\u7a0b<\/a><\/h3>\n<div class=\"c-src\">\u4f86\u6e90\uff1a<span itemprop=\"publisher\">FierceBiotech<\/span> \u00b7 <time datetime=\"2026-04-27\" itemprop=\"datePublished\">2026-04-27<\/time><\/div>\n<div class=\"c-hype\"><span class=\"c-hype-lb\">\u7522\u696d\u91cd\u8981\u6027<\/span><span class=\"c-hype-dots\">\u25cf\u25cf\u25cb\u25cb\u25cb<\/span><span class=\"c-hype-tx\">2\/5 \u00b7 \u6b21\u8981\u52d5\u614b<\/span><\/div>\n<div class=\"c-stocks\"><span class=\"stk stk-other\">WCG <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-other\">The Contract Network <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-us\"><b>IQV<\/b> IQVIA <span class=\"chg chg-up\">\u25b21.00% $162.28<\/span><\/span><span class=\"stk stk-other\">Syneos Health <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-other\"><b>4795<\/b> \u7cbe\u6e96\u91ab\u5b78 <span class=\"chg chg-flat\">\u2014<\/span><\/span><span class=\"stk stk-tw\"><b>6446<\/b> \u85e5\u83ef\u85e5 <span class=\"chg chg-down\">\u25bc2.90% $602.0<\/span><\/span><\/div>\n<section class=\"c-analysis\" itemprop=\"articleBody\">\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u4e8b\u4ef6<\/h4>\n<p>\u81e8\u5e8a\u8a66\u9a57\u670d\u52d9\u63d0\u4f9b\u5546 WCG \u6536\u8cfc\u5c08\u696d\u627f\u5305\u5546\u7db2\u8def\u5e73\u53f0 The Contract Network\uff0c\u65e8\u5728\u6574\u5408\u81e8\u5e8a\u8a66\u9a57\u4f9b\u61c9\u93c8\u4e26\u63d0\u5347\u57f7\u884c\u6548\u7387\u3002\u6b64\u4f75\u8cfc\u53cd\u6620 CRO \u7522\u696d\u6b63\u671d\u5411\u5e73\u53f0\u5316\u3001\u6578\u4f4d\u5316\u8f49\u578b\u4ee5\u61c9\u5c0d\u65e5\u76ca\u8907\u96dc\u7684\u81e8\u5e8a\u8a66\u9a57\u9700\u6c42\u3002<\/p>\n<\/div>\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u6578\u64da<\/h4>\n<p>\u6536\u8cfc\u91d1\u984d\u672a\u516c\u958b\u3002\u5168\u7403 CRO \u5e02\u5834\u898f\u6a21\u7d04 800 \u5104\u7f8e\u5143\uff0c\u5e74\u6210\u9577\u7387 8-10%\u3002\u81e8\u5e8a\u8a66\u9a57\u5e73\u5747\u6210\u672c\u5728\u904e\u53bb\u5341\u5e74\u4e0a\u5347 50%\uff0cPhase III \u8a66\u9a57\u6210\u672c\u5e38\u8d85\u904e 1 \u5104\u7f8e\u5143\u3002\u7d04 85% \u7684\u81e8\u5e8a\u8a66\u9a57\u9762\u81e8\u62db\u52df\u5ef6\u9072\u6216\u9810\u7b97\u8d85\u652f\u554f\u984c\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide\">\n<h4>\u5e02\u5834\u91cd\u8981\u6027<\/h4>\n<p>CRO \u7522\u696d\u6574\u4f75\u8da8\u52e2\u53cd\u6620\u81e8\u5e8a\u8a66\u9a57\u8907\u96dc\u6027\u6301\u7e8c\u63d0\u5347\uff0c\u8feb\u4f7f\u670d\u52d9\u5546\u5fc5\u9808\u5efa\u69cb\u66f4\u5b8c\u6574\u7684\u4e00\u7ad9\u5f0f\u89e3\u6c7a\u65b9\u6848\u3002\u50b3\u7d71\u4ee5\u4eba\u529b\u5bc6\u96c6\u70ba\u4e3b\u7684 CRO \u6a21\u5f0f\u6b63\u88ab\u6578\u4f4d\u5e73\u53f0\u548c AI \u9a45\u52d5\u7684\u65b0\u4e16\u4ee3\u670d\u52d9\u53d6\u4ee3\uff0c\u9019\u5c07\u91cd\u65b0\u5b9a\u7fa9\u81e8\u5e8a\u8a66\u9a57\u7684\u6210\u672c\u7d50\u69cb\u8207\u57f7\u884c\u6a19\u6e96\u3002\u5c0d\u751f\u6280\u516c\u53f8\u800c\u8a00\uff0c\u9078\u64c7\u5177\u5099\u5b8c\u6574\u751f\u614b\u7cfb\u7684 CRO \u5925\u4f34\u5c07\u6210\u70ba\u63a7\u5236\u958b\u767c\u6642\u7a0b\u8207\u6210\u672c\u7684\u95dc\u9375\u56e0\u7d20\u3002\u6b64\u8da8\u52e2\u4e5f\u70ba\u5c08\u7cbe\u7279\u5b9a\u6cbb\u7642\u9818\u57df\u6216\u64c1\u6709\u7368\u7279\u6280\u8853\u80fd\u529b\u7684\u4e2d\u5c0f\u578b CRO \u5e36\u4f86\u88ab\u4f75\u8cfc\u7684\u6a5f\u6703\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide c-counter\">\n<h4>\u26a0 \u53cd\u9762\u89c0\u9ede<\/h4>\n<blockquote>CRO \u7522\u696d\u6574\u4f75\u96d6\u63d0\u5347\u670d\u52d9\u5b8c\u6574\u6027\uff0c\u4f46\u4e5f\u53ef\u80fd\u5c0e\u81f4\u5e02\u5834\u96c6\u4e2d\u5ea6\u904e\u9ad8\uff0c\u524a\u5f31\u751f\u6280\u516c\u53f8\u8b70\u50f9\u80fd\u529b\u4e26\u63a8\u5347\u81e8\u5e8a\u8a66\u9a57\u6210\u672c\u3002<\/blockquote>\n<\/div>\n<div class=\"c-sec c-wide c-watch\">\n<h4>\ud83d\udccd \u63a5\u4e0b\u4f86\u89c0\u5bdf<\/h4>\n<div class=\"c-watch-grid\">\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-short\">\ud83d\udd25 \u77ed\u671f\u50ac\u5316\u5291<span>1-3 \u500b\u6708<\/span><\/div><ul><li>WCG \u6574\u5408\u9032\u5ea6\u8207\u5ba2\u6236\u53cd\u61c9<\/li><li>\u5176\u4ed6 CRO \u4f75\u8cfc\u52d5\u614b<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-mid\">\ud83d\udc41 \u4e2d\u671f\u89c0\u5bdf<span>3-12 \u500b\u6708<\/span><\/div><ul><li>\u6578\u4f4d\u5316\u5e73\u53f0\u4f7f\u7528\u7387\u63d0\u5347\u60c5\u6cc1<\/li><li>\u81e8\u5e8a\u8a66\u9a57\u57f7\u884c\u6548\u7387\u6539\u5584\u6578\u64da<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-long\">\ud83c\udfaf \u9577\u671f\u8b8a\u6578<span>1 \u5e74\u4ee5\u4e0a<\/span><\/div><ul><li>AI \u5728\u81e8\u5e8a\u8a66\u9a57\u8a2d\u8a08\u7684\u61c9\u7528\u666e\u53ca<\/li><li>\u76e3\u7ba1\u6a5f\u69cb\u5c0d\u6578\u4f4d\u5316\u8a66\u9a57\u7684\u653f\u7b56\u8abf\u6574<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<div class=\"c-sec c-wide c-faqs\">\n<h4>\u2753 \u5e38\u898b\u554f\u984c<\/h4>\n<details class=\"c-faq-item\"><summary>CRO \u6574\u4f75\u5c0d\u751f\u6280\u516c\u53f8\u6709\u4ec0\u9ebc\u5f71\u97ff\uff1f<\/summary><p>\u77ed\u671f\u53ef\u80fd\u9762\u81e8\u670d\u52d9\u5546\u9078\u64c7\u6e1b\u5c11\u548c\u6210\u672c\u4e0a\u5347\u58d3\u529b\uff0c\u4f46\u9577\u671f\u5c07\u53d7\u60e0\u65bc\u66f4\u5b8c\u6574\u7684\u4e00\u7ad9\u5f0f\u670d\u52d9\u548c\u66f4\u9ad8\u7684\u8a66\u9a57\u57f7\u884c\u6548\u7387\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u81e8\u5e8a\u8a66\u9a57\u6578\u4f4d\u5316\u7684\u4e3b\u8981\u597d\u8655\u662f\u4ec0\u9ebc\uff1f<\/summary><p>\u53ef\u5927\u5e45\u7e2e\u77ed\u60a3\u8005\u62db\u52df\u6642\u9593\u3001\u63d0\u5347\u6578\u64da\u54c1\u8cea\u3001\u964d\u4f4e\u76e3\u5bdf\u6210\u672c\uff0c\u4e26\u900f\u904e AI \u5206\u6790\u63d0\u65e9\u767c\u73fe\u5b89\u5168\u6027\u4fe1\u865f\uff0c\u6574\u9ad4\u53ef\u7bc0\u7701 20-30% \u8a66\u9a57\u6210\u672c\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u53f0\u7063 CRO \u7522\u696d\u5728\u9019\u6ce2\u6574\u4f75\u6f6e\u4e2d\u7684\u6a5f\u6703\u5728\u54ea\uff1f<\/summary><p>\u53f0\u7063 CRO \u5177\u5099\u4e9e\u592a\u5730\u5340\u81e8\u5e8a\u8a66\u9a57\u57f7\u884c\u7d93\u9a57\u548c\u6210\u672c\u512a\u52e2\uff0c\u5728\u7cbe\u6e96\u91ab\u7642\u548c\u7f55\u898b\u75be\u75c5\u9818\u57df\u6709\u6a5f\u6703\u6210\u70ba\u570b\u969b CRO \u7684\u4f75\u8cfc\u6216\u5408\u4f5c\u6a19\u7684\u3002<\/p><\/details>\n<\/div>\n<\/section>\n<footer class=\"c-ft\"><a href=\"https:\/\/www.fiercebiotech.com\/cro\/wcg-acquires-contract-network-aiming-streamline-clinical-trial-process\" rel=\"noopener nofollow\" target=\"_blank\">\u95b1\u8b80\u539f\u6587 \u2192<\/a><\/footer>\n<\/article>\n<\/section>\n<section aria-labelledby=\"sec-briefs\">\n<h2 class=\"lbl\" id=\"sec-briefs\">\u4eca\u65e5\u5feb\u8a0a<\/h2>\n<ul class=\"briefs\" style=\"list-style:none\">\n<li class=\"b-item\">\n<span class=\"b-dot\" style=\"background:#ED7D31\"><\/span>\n<div><a class=\"b-link\" href=\"https:\/\/www.fiercebiotech.com\/medtech\/thermo-fisher-sees-higher-q1-earnings-amid-strong-biopharma-demand\" rel=\"noopener nofollow\" target=\"_blank\">&lt;a href=&#8221;https:\/\/www.fiercebiotech.com\/medtech\/thermo-fisher-sees-higher-q1-earnings-amid-strong-biopharma-demand&#8221; hreflang=&#8221;en&#8221;&gt;Thermo Fisher sees higher Q1 earnings amid strong biopharma demand&lt;\/a&gt;<\/a>\n<span class=\"b-meta\">\u91ab\u7642\u5668\u6750 \u00b7 FierceBiotech<\/span><\/div>\n<\/li>\n<\/ul>\n<\/section>\n<section aria-labelledby=\"sec-stats\" class=\"stats\" style=\"margin-top:48px\">\n<h2 class=\"lbl\" id=\"sec-stats\" style=\"font-size:16px;border-bottom-width:1px\">\u5206\u985e\u7d71\u8a08<\/h2>\n<div class=\"st\"><div class=\"st-bar\" style=\"width:25.0%;background:#4472C4\"><\/div><span class=\"st-lb\">\u85e5\u7269<\/span><span class=\"st-ct\">1<\/span><\/div><div class=\"st\"><div class=\"st-bar\" style=\"width:25.0%;background:#ED7D31\"><\/div><span class=\"st-lb\">\u91ab\u7642\u5668\u6750<\/span><span class=\"st-ct\">1<\/span><\/div><div class=\"st\"><div class=\"st-bar\" style=\"width:25.0%;background:#70AD47\"><\/div><span class=\"st-lb\">\u65b0\u8208\u7642\u6cd5<\/span><span class=\"st-ct\">1<\/span><\/div><div class=\"st\"><div class=\"st-bar\" style=\"width:25.0%;background:#5B9BD5\"><\/div><span class=\"st-lb\">\u6578\u4f4d\u5065\u5eb7\u91ab\u7642\u79d1\u6280<\/span><span class=\"st-ct\">1<\/span><\/div>\n<\/section>\n<!-- footer \u5df2\u79fb\u9664(v2.14.0) -->\n<\/main>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>2026 \u5e74 04 \u6708 27 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 \u5171\u6536\u9304 4 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e \u00b7 3 \u5247\u7cbe\u9078\u6df1\u5ea6\u5206\u6790 \u7cbe\u9078 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":7356,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"rank_math_title":"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-04-27\uff5cAvalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7","rank_math_description":"2026 \u5e74 04 \u6708 27 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\uff1aAvalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7\u52a9\u91cd\u65b0\u914d\u65b9\u547c\u5438\u9053\u85e5\u3001Eli Lilly 70 \u5104\u7f8e\u5143\u6536\u8cfc Kelonia \u5f8c\uff0c\u9084\u6709\u54ea\u4e9b i\u3002\u5171\u6536\u9304 4 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e,\u542b\u6df1\u5ea6\u5206\u6790\u3001\u53cd\u9762\u89c0\u9ede\u8207\u77ed\u4e2d\u9577\u671f\u89c0\u5bdf\u91cd\u9ede\u3002","rank_math_focus_keyword":"\u751f\u91ab\u5927\u5065\u5eb7","rank_math_robots":"","daily_schema_jsonld":"[\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"CollectionPage\",\n    \"name\": \"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-04-27\uff5cAvalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7\",\n    \"description\": \"2026 \u5e74 04 \u6708 27 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\uff1aAvalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7\u52a9\u91cd\u65b0\u914d\u65b9\u547c\u5438\u9053\u85e5\u3001Eli Lilly 70 \u5104\u7f8e\u5143\u6536\u8cfc Kelonia \u5f8c\uff0c\u9084\u6709\u54ea\u4e9b i\u3002\u5171\u6536\u9304 4 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e,\u542b\u6df1\u5ea6\u5206\u6790\u3001\u53cd\u9762\u89c0\u9ede\u8207\u77ed\u4e2d\u9577\u671f\u89c0\u5bdf\u91cd\u9ede\u3002\",\n    \"url\": \"https:\/\/witology.com.tw\/daily\/2026-04-27\",\n    \"datePublished\": \"2026-04-27\",\n    \"inLanguage\": \"zh-TW\",\n    \"publisher\": {\n      \"@type\": \"Organization\",\n      \"name\": \"\u667a\u749e\u79d1\u6280\",\n      \"logo\": {\n        \"@type\": \"ImageObject\",\n        \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n      }\n    },\n    \"isPartOf\": {\n      \"@type\": \"WebSite\",\n      \"name\": \"\u667a\u749e\u79d1\u6280\",\n      \"url\": \"https:\/\/witology.com.tw\"\n    },\n    \"hasPart\": [\n      {\n        \"@type\": \"NewsArticle\",\n        \"headline\": \"Avalyn \u8a08\u5283\u900f\u904e 1.82 \u5104\u7f8e\u5143 IPO \u8cc7\u52a9\u91cd\u65b0\u914d\u65b9\u547c\u5438\u9053\u85e5\u7269\u7b2c\u4e09\u671f\u8a66\u9a57\",\n        \"datePublished\": \"2026-04-27\",\n        \"dateModified\": \"2026-04-27\",\n        \"image\": [\n          \"https:\/\/witology.com.tw\/logo.png\"\n        ],\n        \"author\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\u7de8\u8f2f\u90e8\"\n        },\n        \"publisher\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\",\n          \"logo\": {\n            \"@type\": \"ImageObject\",\n            \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n          }\n        },\n        \"mainEntityOfPage\": {\n          \"@type\": \"WebPage\",\n          \"@id\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-1\"\n        },\n        \"description\": \"Avalyn Pharma \u8a08\u5283\u900f\u904e IPO \u52df\u96c6 1.82 \u5104\u7f8e\u5143\u8cc7\u91d1\uff0c\u4e3b\u8981\u7528\u65bc\u63a8\u9032\u5176\u91cd\u65b0\u914d\u65b9\u7684\u547c\u5438\u9053\u85e5\u7269\u9032\u5165\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u3002\u8a72\u516c\u53f8\u5c08\u6ce8\u65bc\u900f\u904e\u5275\u65b0\u7d66\u85e5\u6280\u8853\u6539\u826f\u73fe\u6709\u547c\u5438\u9053\u6cbb\u7642\u85e5\u7269\uff0c\u63d0\u5347\u60a3\u8005\u7528\u85e5\u9806\u5f9e\u6027\u8207\u7642\u6548\u3002\",\n        \"url\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-1\",\n        \"isBasedOn\": \"https:\/\/www.fiercebiotech.com\/biotech\/avalyn-aims-181m-ipo-fund-phase-3-trials-reformulated-respiratory-drugs\",\n        \"about\": [\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Avalyn Pharma\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"AstraZeneca\",\n            \"tickerSymbol\": \"AZN\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"GSK\",\n            \"tickerSymbol\": \"GSK\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u6cf0\u5b97\u751f\u7269\u79d1\u6280\",\n            \"tickerSymbol\": \"4169\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u9806\u85e5\",\n            \"tickerSymbol\": \"6535\"\n          }\n        ]\n      },\n      {\n        \"@type\": \"NewsArticle\",\n        \"headline\": \"Eli Lilly 70 \u5104\u7f8e\u5143\u6536\u8cfc Kelonia \u5f8c\uff0c\u9084\u6709\u54ea\u4e9b in vivo CAR-T \u751f\u6280\u516c\u53f8\u53ef\u6536\u8cfc\uff1f\",\n        \"datePublished\": \"2026-04-27\",\n        \"dateModified\": \"2026-04-27\",\n        \"image\": [\n          \"https:\/\/witology.com.tw\/logo.png\"\n        ],\n        \"author\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\u7de8\u8f2f\u90e8\"\n        },\n        \"publisher\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\",\n          \"logo\": {\n            \"@type\": \"ImageObject\",\n            \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n          }\n        },\n        \"mainEntityOfPage\": {\n          \"@type\": \"WebPage\",\n          \"@id\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-2\"\n        },\n        \"description\": \"Eli Lilly \u4ee5 70 \u5104\u7f8e\u5143\u6536\u8cfc in vivo CAR-T \u6280\u8853\u516c\u53f8 Kelonia\uff0c\u5f15\u767c\u5e02\u5834\u95dc\u6ce8\u5269\u9918\u6a19\u7684\u7a00\u7f3a\u6027\u3002In vivo CAR-T \u6280\u8853\u53ef\u76f4\u63a5\u5728\u60a3\u8005\u9ad4\u5167\u6539\u9020 T \u7d30\u80de\uff0c\u907f\u514d\u50b3\u7d71 ex vivo CAR-T \u7684\u9ad8\u6210\u672c\u8207\u88fd\u9020\u8907\u96dc\u6027\u554f\u984c\u3002\",\n        \"url\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-2\",\n        \"isBasedOn\": \"https:\/\/www.fiercebiotech.com\/biotech\/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo\",\n        \"about\": [\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Eli Lilly\",\n            \"tickerSymbol\": \"LLY\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Kelonia\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Gilead Sciences\",\n            \"tickerSymbol\": \"GILD\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Bristol Myers Squibb\",\n            \"tickerSymbol\": \"BMY\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Novartis\",\n            \"tickerSymbol\": \"NVS\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u57fa\u4e9e\",\n            \"tickerSymbol\": \"3176\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u8a0a\u806f\",\n            \"tickerSymbol\": \"1784\"\n          }\n        ]\n      },\n      {\n        \"@type\": \"NewsArticle\",\n        \"headline\": \"WCG \u6536\u8cfc The Contract Network \u4ee5\u512a\u5316\u81e8\u5e8a\u8a66\u9a57\u57f7\u884c\u6d41\u7a0b\",\n        \"datePublished\": \"2026-04-27\",\n        \"dateModified\": \"2026-04-27\",\n        \"image\": [\n          \"https:\/\/witology.com.tw\/logo.png\"\n        ],\n        \"author\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\u7de8\u8f2f\u90e8\"\n        },\n        \"publisher\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\",\n          \"logo\": {\n            \"@type\": \"ImageObject\",\n            \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n          }\n        },\n        \"mainEntityOfPage\": {\n          \"@type\": \"WebPage\",\n          \"@id\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-3\"\n        },\n        \"description\": \"\u81e8\u5e8a\u8a66\u9a57\u670d\u52d9\u63d0\u4f9b\u5546 WCG \u6536\u8cfc\u5c08\u696d\u627f\u5305\u5546\u7db2\u8def\u5e73\u53f0 The Contract Network\uff0c\u65e8\u5728\u6574\u5408\u81e8\u5e8a\u8a66\u9a57\u4f9b\u61c9\u93c8\u4e26\u63d0\u5347\u57f7\u884c\u6548\u7387\u3002\u6b64\u4f75\u8cfc\u53cd\u6620 CRO \u7522\u696d\u6b63\u671d\u5411\u5e73\u53f0\u5316\u3001\u6578\u4f4d\u5316\u8f49\u578b\u4ee5\u61c9\u5c0d\u65e5\u76ca\u8907\u96dc\u7684\u81e8\u5e8a\u8a66\u9a57\u9700\u6c42\u3002\",\n        \"url\": \"https:\/\/witology.com.tw\/daily\/2026-04-27#article-3\",\n        \"isBasedOn\": \"https:\/\/www.fiercebiotech.com\/cro\/wcg-acquires-contract-network-aiming-streamline-clinical-trial-process\",\n        \"about\": [\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"WCG\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"The Contract Network\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"IQVIA\",\n            \"tickerSymbol\": \"IQV\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Syneos Health\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u7cbe\u6e96\u91ab\u5b78\",\n            \"tickerSymbol\": \"4795\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u85e5\u83ef\u85e5\",\n            \"tickerSymbol\": \"6446\"\n          }\n        ]\n      }\n    ]\n  },\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"BreadcrumbList\",\n    \"itemListElement\": [\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 1,\n        \"name\": \"\u9996\u9801\",\n        \"item\": \"https:\/\/witology.com.tw\"\n      },\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 2,\n        \"name\": \"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\",\n        \"item\": \"https:\/\/witology.com.tw\/daily\"\n      },\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 3,\n        \"name\": \"2026-04-27\",\n        \"item\": \"https:\/\/witology.com.tw\/daily\/2026-04-27\"\n      }\n    ]\n  },\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"FAQPage\",\n    \"mainEntity\": [\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u91cd\u65b0\u914d\u65b9\u85e5\u7269\u548c\u5b78\u540d\u85e5\u6709\u4ec0\u9ebc\u4e0d\u540c\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u91cd\u65b0\u914d\u65b9\u85e5\u7269\u662f\u6539\u826f\u73fe\u6709\u85e5\u7269\u7684\u5291\u578b\u3001\u7d66\u85e5\u65b9\u5f0f\u6216\u91cb\u653e\u6a5f\u5236\uff0c\u4ecd\u4eab\u6709\u4e00\u5b9a\u5c08\u5229\u4fdd\u8b77\u671f\uff1b\u5b78\u540d\u85e5\u5247\u662f\u5b8c\u5168\u8907\u88fd\u539f\u5ee0\u85e5\uff0c\u7121\u5c08\u5229\u4fdd\u8b77\u4e14\u50f9\u683c\u7af6\u722d\u6fc0\u70c8\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"Avalyn \u7684 1.82 \u5104\u7f8e\u5143\u52df\u8cc7\u898f\u6a21\u5728\u751f\u6280 IPO \u4e2d\u7b97\u5927\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u5c6c\u65bc\u4e2d\u7b49\u898f\u6a21\uff0c2024 \u5e74\u751f\u6280 IPO \u5e73\u5747\u52df\u8cc7\u984d\u7d04 1-3 \u5104\u7f8e\u5143\u3002\u8003\u91cf\u547c\u5438\u9053\u85e5\u7269\u7b2c\u4e09\u671f\u8a66\u9a57\u6210\u672c\u76f8\u5c0d\u8f03\u4f4e\uff0c\u6b64\u91d1\u984d\u61c9\u8db3\u4ee5\u652f\u6490\u81f3\u95dc\u9375\u91cc\u7a0b\u7891\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u70ba\u4ec0\u9ebc\u547c\u5438\u9053\u75be\u75c5\u7279\u5225\u9069\u5408\u91cd\u65b0\u914d\u65b9\u7b56\u7565\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u547c\u5438\u9053\u7528\u85e5\u9ad8\u5ea6\u4f9d\u8cf4\u5438\u5165\u88dd\u7f6e\u6280\u8853\uff0c\u60a3\u8005\u5c0d\u4fbf\u5229\u6027\u548c\u526f\u4f5c\u7528\u654f\u611f\u5ea6\u9ad8\uff0c\u4e14\u73fe\u6709\u7522\u54c1\u591a\u5df2\u904e\u5c08\u5229\u4fdd\u8b77\u671f\uff0c\u70ba\u65b0\u914d\u65b9\u7559\u4e0b\u5e02\u5834\u7a7a\u9593\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"In vivo CAR-T \u548c\u50b3\u7d71 CAR-T \u6709\u4ec0\u9ebc\u5dee\u5225\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u50b3\u7d71 CAR-T \u9700\u5c07\u60a3\u8005 T \u7d30\u80de\u53d6\u51fa\u9ad4\u5916\u6539\u9020\u518d\u8f38\u56de\uff0cin vivo CAR-T \u5247\u76f4\u63a5\u5728\u60a3\u8005\u9ad4\u5167\u900f\u904e\u57fa\u56e0\u8f09\u9ad4\u6539\u9020 T \u7d30\u80de\uff0c\u7701\u53bb\u8907\u96dc\u7684\u7d30\u80de\u88fd\u9020\u6d41\u7a0b\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"70 \u5104\u7f8e\u5143\u6536\u8cfc\u50f9\u5728\u751f\u6280\u4f75\u8cfc\u4e2d\u7b97\u9ad8\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u5c6c\u65bc\u8fd1\u5e74\u4f86\u7d30\u80de\u6cbb\u7642\u9818\u57df\u7684\u9802\u7d1a\u4ea4\u6613\uff0c\u53cd\u6620 Lilly \u5c0d in vivo \u5e73\u53f0\u6280\u8853\u7684\u9ad8\u5ea6\u91cd\u8996\uff0c\u4ee5\u53ca\u5e02\u5834\u5c0d\u6b64\u6280\u8853\u5546\u696d\u5316\u6f5b\u529b\u7684\u6a02\u89c0\u9810\u671f\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u9084\u6709\u54ea\u4e9b\u516c\u53f8\u64c1\u6709\u985e\u4f3c\u7684 in vivo CAR-T \u6280\u8853\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u4e3b\u8981\u6a19\u7684\u5305\u62ec Poseida Therapeutics\u3001Ensoma\u3001\u4ee5\u53ca\u90e8\u5206\u5c08\u7cbe\u57fa\u56e0\u8f09\u9ad4\u6280\u8853\u7684\u79c1\u4eba\u516c\u53f8\uff0c\u4f46\u6578\u91cf\u7a00\u5c11\u4e14\u591a\u5df2\u88ab\u5927\u85e5\u5ee0\u95dc\u6ce8\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"CRO \u6574\u4f75\u5c0d\u751f\u6280\u516c\u53f8\u6709\u4ec0\u9ebc\u5f71\u97ff\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u77ed\u671f\u53ef\u80fd\u9762\u81e8\u670d\u52d9\u5546\u9078\u64c7\u6e1b\u5c11\u548c\u6210\u672c\u4e0a\u5347\u58d3\u529b\uff0c\u4f46\u9577\u671f\u5c07\u53d7\u60e0\u65bc\u66f4\u5b8c\u6574\u7684\u4e00\u7ad9\u5f0f\u670d\u52d9\u548c\u66f4\u9ad8\u7684\u8a66\u9a57\u57f7\u884c\u6548\u7387\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u81e8\u5e8a\u8a66\u9a57\u6578\u4f4d\u5316\u7684\u4e3b\u8981\u597d\u8655\u662f\u4ec0\u9ebc\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u53ef\u5927\u5e45\u7e2e\u77ed\u60a3\u8005\u62db\u52df\u6642\u9593\u3001\u63d0\u5347\u6578\u64da\u54c1\u8cea\u3001\u964d\u4f4e\u76e3\u5bdf\u6210\u672c\uff0c\u4e26\u900f\u904e AI \u5206\u6790\u63d0\u65e9\u767c\u73fe\u5b89\u5168\u6027\u4fe1\u865f\uff0c\u6574\u9ad4\u53ef\u7bc0\u7701 20-30% \u8a66\u9a57\u6210\u672c\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u53f0\u7063 CRO \u7522\u696d\u5728\u9019\u6ce2\u6574\u4f75\u6f6e\u4e2d\u7684\u6a5f\u6703\u5728\u54ea\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u53f0\u7063 CRO \u5177\u5099\u4e9e\u592a\u5730\u5340\u81e8\u5e8a\u8a66\u9a57\u57f7\u884c\u7d93\u9a57\u548c\u6210\u672c\u512a\u52e2\uff0c\u5728\u7cbe\u6e96\u91ab\u7642\u548c\u7f55\u898b\u75be\u75c5\u9818\u57df\u6709\u6a5f\u6703\u6210\u70ba\u570b\u969b CRO \u7684\u4f75\u8cfc\u6216\u5408\u4f5c\u6a19\u7684\u3002\"\n        }\n      }\n    ]\n  }\n]","daily_standalone_url":"","footnotes":""},"class_list":["post-7411","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/7411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/comments?post=7411"}],"version-history":[{"count":0,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/7411\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/7356"}],"wp:attachment":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/media?parent=7411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}